Thalidomide shows promise as a steroid-sparing option for IgG4-related disease, with a significant reduction in relapse rates and enhanced remission, according to a placebo-controlled study. Medscape Medical News
Category: News
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
GENEVA–(BUSINESS WIRE)–Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
GENEVA–(BUSINESS WIRE)–Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy
ZÜRICH–(BUSINESS WIRE)–CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate for the treatment of geogr…
Study Finds No Vision Issues in Children With Vitiligo
Children with vitiligo do not have a higher risk for visual acuity deficits than healthy peers, a study suggests. Medscape Medical News
GLP-1 Drugs Cut Glaucoma Risk in Nondiabetic Obesity
GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight loss medications in patients without diabetes diagnosed with obesity. Medscape Medical News
#DiedSuddenly Was BS: Why Did We Believe It?
A hashtag that gained a lot of traction during the COVID-19 pandemic is, thankfully, in decline, but can we avoid buying into such nonsense again? Medscape
EyeCare Partners Announces New Physician Leadership Appointments
ST. LOUIS–(BUSINESS WIRE)– #elevatingeyeare–EyeCare Partners (ECP) is pleased to announce the appointment of Michael Nordlund, M.D., Ph.D., as Chief Medical Officer (CMO) and Joseph Gira, M.D., as Chief Physician Relations Officer (CPRO), strengthen…
Fluoride in Water Supply Not a Risk, Says Ethicist
Ethicist Art Caplan allays fears amid a resurgence in public concern over fluoridated water. Medscape Business of Medicine
Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucoma
SAN DIEGO–(BUSINESS WIRE)–Seonix Bio, a leader in the development of genetic testing for glaucoma, today announced the U.S. launch of SightScore, the first commercially available clinical polygenic risk score testing service for primary open-angle gl…
Stress: A New Cancer Risk Factor?
Even everyday stress, the kind that many people experience, impairs the cancer-fighting immune system. Medscape
Virologist Treats Own Breast Cancer: Ethical?
Ethicist Art Caplan discusses ethical questions raised when virologist Beata Halassy treated her own breast cancer using experimental methods. Medscape Business of Medicine
セルトリオンが欧州委員会による承認獲得、EUで2つのバイオシミラー製品のポートフォリオを拡大
韓国、仁川–(BUSINESS WIRE)–（ビジネスワイヤ） — （ビジネスワイヤ） — セルトリオンは、欧州委員会（EC）から2つのバイオシミラーにおいて3つの製品の販売承認を取得したと発表しました。承認を受けたEydenzelt® （CT-P42、アフリベルセプト）は、Eylea®のバイオシミラーであり、新生血管（滲出型）加齢黄斑変性（AMD）、網膜静脈閉塞症（RVO：分枝RVOまたは中心RVO）に伴う黄斑浮腫、糖尿病黄斑浮腫（DME）、および近視性脈絡膜新生血管（myopic CNV…
Mit der Zulassung von zwei weiteren Biosimilars erweitert Celltrion sein Biosimilar-Portfolio in der EU
INCHEON, Südkorea–(BUSINESS WIRE)–Wie Celltrion heute mitteilte, hat die Europäische Kommission die Marktzulassung für zwei Biosimilars erteilt:: Eydenzelt® (CT-P42, Aflibercept), ein Biosimilar zu Eylea®, zur Behandlung verschiedener Netzhauterkrank…
Celltrion breidt haar portfolio biosimilaire geneesmiddelen in de Europese Unie uit na goedkeuring van de Europese Commissie van twee biosimilars
INCHEON, Zuid-Korea–(BUSINESS WIRE)–Celltrion maakte vandaag bekend dat de Europese Commissie (EC) een vergunning heeft verleend voor het in de handel brengen van drie producten in twee biosimilars: Eydenzelt® (CT-P42, aflibercept), een biosimilar di…
Celltrion élargit son portefeuille de produits biosimilaires dans l’Union européenne suite à l’autorisation de deux nouvelles molécules biosimilaires par la Commission européenne
INCHEON, Corée du Sud–(BUSINESS WIRE)–Celltrion a annoncé aujourd’hui que la Commission européenne (CE) a accordé une autorisation de mise sur le marché pour trois produits dont deux molécules biosimilaires : Eydenzelt® (CT-P42, aflibercept), un médi…
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple…
National Vision’s 20/20 Quest Foundation Grants $25,000 to Optometry Giving Sight to Support Global Vision Care Initiatives
DULUTH, Ga.–(BUSINESS WIRE)–National Vision, Inc. announced today that its charitable foundation, 20/20 Quest, has awarded a $25,000 grant to Optometry Giving Sight (OGS). The funding supports OGS’s ongoing mission to combat preventable blindness and…
GeminiBio Appoints Mike Stella to Board
WEST SACRAMENTO, Calif.–(BUSINESS WIRE)–Gemini Bioproducts, LLC (“GeminiBio”), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Fort Lauderdale-based healthcare pr…
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
FORT LEE, N.J.–(BUSINESS WIRE)–Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced that th…